Entries |
Document | Title | Date |
20100240598 | PEPTIDES AND PEPTIDE MIMETICS TO INHIBIT THE ONSET AND/OR PROGRESSION OF FIBROTIC AND/OR PRE-FIBROTIC PATHOLOGIES - This invention provides methods of inhibiting the onset or progression of a fibrotic disease (or pre-fibrotic pathology) in a mammal. The method involves administering oen or more peptides (e.g., class A amphipathic helical peptides, G* peptides, etc.) as described herein to a mammal in need thereof, in an amount effective to inhibit the onset and/or progression of the fibrotic disease (or pre-fibrotic condition) in the mammal. In certain embodiments the fibrotic disease is selected from the group consisting of retroperitoneal fibrosis (RPF), hepatic fibrosis and/or chirrhosis, renal fibrosis, and pancreatic fibrosis | 09-23-2010 |
20100273722 | MODIFIED MINIATURE PROTEINS - The present invention generally relates to modified miniature proteins, including modified avian pancreatic polypeptides (aPP) and modified pancreatic peptide YYs (PYY). One aspect of the invention is generally directed to various aPPs that have been modified such that they do not substantially form multimers in solution, for example through the addition of a proline switch. Another aspect of the invention is generally directed to modified PYYs, such as YY3. Yet another aspect of the invention is generally directed to composites of modified miniature proteins formed from portions of different miniature proteins such as aPP and/or PYY, optionally with a proline switch. Still other aspects of the invention are generally directed to methods of making such proteins, methods of using such proteins, kits involving such proteins, and the like. | 10-28-2010 |
20100273723 | PEPTIDES OF IL-2 - The present invention relates to new peptides of IL-2, derivatives thereof, and their use as therapeutic agents. | 10-28-2010 |
20100286069 | CATIONIC PEPTIDE FOR DELIVERING AN AGENT INTO A CELL - There is presently provided a triblock peptide comprising a hydrophobic amino acid block, a histidine block and a cationic amino acid block. The triblock peptide may be used to form a nanoparticle for delivery of an agent into a cell. | 11-11-2010 |
20100286070 | AFFINITY TAG - The present invention relates to an affinity tag especially useful for human applications. The invention further includes methods for preparing fusion molecules, as well as compositions and reaction mixtures which contain said fusion molecules, nucleic acid molecules which encode these fusion molecules and recombinant host cells which contain these nucleic acid molecules. | 11-11-2010 |
20100286071 | Finger-1 Peptide Analogs of the TGF-Beta Superfamily - Members of the TGF-β superfamily and peptide fragments based on member proteins are employed to purify solutions containing member proteins or as therapeutics. | 11-11-2010 |
20100292172 | Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same - Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders. | 11-18-2010 |
20100298239 | PEPTIDE WITH MULTIPLE EPITOPES - The present invention relates to peptides comprising multiple MHC Class II-binding T cell epitopes for tolerisation therapy. | 11-25-2010 |
20100298240 | PMMA BINDING PEPTIDES - Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface. | 11-25-2010 |
20100298241 | PMMA BINDING PEPTIDES - Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface. | 11-25-2010 |
20100311672 | VESICULINS - The inventions relate generally to vesiculin peptides and vesiculin peptide chains, and fragments, variants and derivatives thereof, related compositions and formulations and their preparation and use, nucleic acids encoding such vesiculin peptides and vesiculin peptide chains, and fragments, variants and derivatives thereof and related vectors and host cells, hybridomas and antibodies, and methods for the prevention and treatment of conditions, diseases and disorders that would be improved, eased, or lessened by the administration of a composition of the invention, including but not limited to glucose metabolism diseases. | 12-09-2010 |
20100317600 | Process for Preparing Cardiodilatin Fragments; Highly Purified Cardiodilatin Fragments and Intermediate Products for the Preparation of Same - The invention relates to a process for the preparation of cardiodilatin fragments, to highly purified cardiodilatin fragments, and to appropriate intermediates for the preparation of said fragments. Furthermore, the invention relates to highly purified cardiodilatin fragments which are free of peptide impurities and exhibit a single migration peak in capillary electrophoresis, as well as to appropriate processes for the preparation of same. | 12-16-2010 |
20100317601 | Casein Derived Peptides And Uses Thereof - Biologically active peptides that are derived from or are similar to sequences identical with the N-terminus of the αS1 fraction of milk casein. These peptides are capable of stimulating and enhancing immune response, protecting against viral infection, normalizing serum cholesterol levels, and stimulating hematopoiesis. The casein-derived peptides are non-toxic and can be used to treat and prevent immune pathologies, hypercholesterolemia, hematological disorders and viral-related diseases, alone or in combination with other peptides or blood cell stimulating factors. | 12-16-2010 |
20100331262 | PEPTIDE VACCINE USING MIMIC MOLECULES OF AMYLOID Beta PEPTIDE - This invention is intended to discover a peptide that induces production of an antibody specific for an abnormal amyloid β peptide from mimic peptides of the amyloid β peptide and to utilize the same as a vaccine or immunogen. This invention relates to a pharmaceutical composition containing a peptide consisting of 8 to 30 amino acid residues, wherein the peptide comprises at least one of an amino acid sequence represented by formula (I): Tyr-Gly-Thr-Lys-Pro-Trp-Met (SEQ ID NO: 28) (I), and an amino acid sequence represented by formula (II): Leu-Asp-Ile-Phe-Ala-Pro-Ile (SEQ ID NO: 29) (II); or a conjugate of such peptide and a carrier. | 12-30-2010 |
20110009343 | MODULATORS OF AMYLOID AGGREGATION - Compounds that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compounds modulate the aggregation of natural β amyloid peptides (β-AP). In a preferred embodiment, the β amyloid modulator compounds of the invention are comprised of an Aβ aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural β amyloid peptides when contacted with the peptides. Furthermore, the modulators are capable of altering natural β-AP aggregation when the natural β-APs are in a molar excess amount relative to the modulators. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed. | 01-13-2011 |
20110028409 | DETECTION OF ANTI-RIBOSOMAL P PROTEIN ANTIBODIES BY MEANS OF SYNTHETIC PEPTIDES - The present invention refers peptides and methods for the identification of diagnostic antibodies in auto-immune diseases such as Systemic Lupus Erythematosus (SLE), and therefore useful tools for diagnosis or therapeutic treatment of SLE. | 02-03-2011 |
20110039791 | ACETYLCHOLINESTERASE (ACHE)-DERIVED PEPTIDE AS AN INDUCER OF GRANULOCYTOPOIESIS, USES AND METHODS THEREOF - The present invention describes the use of an AChE-R-derived peptide, also known as ARP, as an inducer of hemopoietic cell differentiation and expansion, specifically for the granulocytic population. In addition, the use of ARP as an inducer of thrombopoietin and pro-inflammatory cytokines is also presented. ARP may further be used in the pre-transplant priming of hematopoietic stem cells. Other uses and methods utilizing ARP are also described herein. | 02-17-2011 |
20110046075 | Secreted Staphylococcus Aureus Proteins And Peptides For Use In Inhibiting Activation Of The Complement System - Compounds comprising peptides and peptide analogs capable of binding the C3 protein and inhibiting complement activation are disclosed. These compounds mimic the structure and activity of secreted | 02-24-2011 |
20110105415 | Gene regulator - The invention relates to the modulation of gene expression in a cell, also called gene control, in particular in relation to the treatment of a variety of diseases. The invention provides a method for modulating expression of a gene in a cell comprising providing the cell with a signalling molecule comprising a peptide or functional analogue thereof. Furthermore, the invention provides a method for identifying or obtaining a signalling molecule comprising a peptide or functional derivative or analogue thereof capable of modulating expression of a gene in a cell comprising providing the cell with a peptide or derivative or analogue thereof and determining the activity and/or nuclear translocation of a gene transcription factor. | 05-05-2011 |
20110124582 | NOVEL POLYPEPTIDE HAVING ANTI-TUMOR ACTIVITY - The present invention relates to a novel polypeptide having anti-tumor activity through inducing apoptosis of endothelial cell and use thereof. More particularly, the present invention relates to a method for inducing apoptosis of endothelial cell, and for preventing or treating cancer, comprising administering to a subject in need thereof an effective amount of (a) an isolated polypeptide having the amino acid sequence of SEQ ID NO: 9 or the amino acid sequence having at least 90% sequence homology to the amino acid sequence of SEQ ID NO: 9; or (b) an isolated polynucleotide encoding the polypeptide of (a). | 05-26-2011 |
20110136746 | Kallikrein-Binding "Kunitz Domain" Proteins and Analogues Thereof - This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides. | 06-09-2011 |
20110178031 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID - The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid. | 07-21-2011 |
20110183921 | PEPTIDES CAPABLE OF MODULATING THE FUNCTION OF TIRC7 - Provided are peptides capable of inhibiting proliferation of peripheral blood mononuclear cells (PBMCs) derived from the third extracellular domain of T-cell immune response cDNA7 (TIRC7) costimulatory molecule are described. Compositions comprising such peptides and their use for the treatment of immune diseases are provided. | 07-28-2011 |
20110183922 | PEPTIDES THAT ENHANCE ACETYLCHOLINESTERASE EXPRESSION - The present invention provides novel chimeric peptides and novel methods for treating animals including humans by administering the novel chimeric peptides. In particular, the invention is useful for enhancing endogenous acetylcholinesterase expression in individuals exposed to organophosphate compounds, such as nerve gases and pesticides. | 07-28-2011 |
20110224152 | SYNTHETIC ARGININE SUBSTITUTED PEPTIDES AND THEIR USE - The present invention relates to new arginine substituted peptides designed based on the sequence of human lactoferrin and to use thereof, in particular for treatment and/or prevention of infections, inflammations, tumours, pain, wounds and/or scars. | 09-15-2011 |
20110237523 | CONTRACEPTIVE PEPTIDES DERIVED FROM THE VENOM OF THE SPIDER Latrodectus mirabilis, NUCLEOTIDE SEQUENCES TO TRANSFORM A MICROORGANISM TO PRODUCE SAID PEPTIDES; METHODS TO OBTAIN THE PEPTIDES; PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF AND USE THEREOF - The present invention is directed to an active agent with contraceptive properties. Said active agent corresponds to a molecular fraction of the venom from the spider | 09-29-2011 |
20110251139 | TREATMENT OF INFLAMMATORY BOWEL DISEASES WITH MAMMAL BETA DEFENSINS - The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins. | 10-13-2011 |
20110263515 | CAPTURE AGENTS AND RELATED COMPOSITIONS, METHODS AND SYSTEMS - Multi-ligand capture agents comprising two or more ligands are described, and related compositions, methods and systems. | 10-27-2011 |
20110288035 | PIMAP39 MODULATES INFLAMMATORY RESPONSE - The present invention relates to a novel peptide sequence named PIMAP39 (herein referred to as SEQ ID NO.: 1) and methods of use of the novel sequence and functional variants thereof. The present invention also relates to methods for reducing and/or modulating inflammatory responses by administration of the peptide of the present invention. Furthermore, the present invention relates to the modulation of the expression of cytokines effected as part of an inflammatory response by administration of the peptide of the present invention. | 11-24-2011 |
20110294747 | PEGYLATED MUTATED CLOSTRIDIUM BOTULINUM TOXIN - The invention relates to a modified botulinum toxin comprising a natural heavy chain and a modified light chain, characterized in that the modification of the light chain resides in that it comprises (i) an extension of the chain on its N-terminus which has the structure —(C) | 12-01-2011 |
20110301101 | T cell immune balance peptides - This invention is related to a peptides mixture. Without the need to consider the patients' genetic background, it can interfere with MHC-pathogenic peptide-TCR formation, which includes the interference with pathogen peptide binding with MHC and pMHC binding with specific TCR, suppression of the immune synapse formation when the specific T cell immune response occurs, reduction of the number and density of the MHC-specific immune response mediated pathogenic peptide-TCR in the immune synapse, and suppression of the highly activated signal transduction in the immune synapse. Hence it can negatively regulate the T cell specific immune response, reduce the specific immune cell activation, proliferation and effect, and make the radical T cell specific immune response more stable and last longer. It can be used to treat diseases with excessive T cell-specific immune reaction, such as severe flu, SARS, hand-foot-and-mouth disease, viral pneumonia, bacterial infections, severe autoimmune disease and etc. | 12-08-2011 |
20120004187 | SPIROCYCLICALLY SUBSTITUTED 1,3-PROPANE DIOXIDE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT - The invention relates to spirocyclically substituted 1,3-propane dioxide derivatives, and to the physiologically compatible salts thereof. | 01-05-2012 |
20120015891 | DEPOT SYSTEMS COMPRISING GLATIRAMER OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF - The present invention provides long acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of glatiramer. In particular, the present invention provides a long acting pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate in depot form suitable for administering at a medically acceptable location in a subject in need thereof. The depot form is suitable for subcutaneous or intramuscular implantation or injection. | 01-19-2012 |
20120040918 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID - The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid. | 02-16-2012 |
20120058956 | PEPTIDES DERIVED FROM FICOLIN AS SURFACTANTS - Provided are peptides having a sequence that is a subsequence of a ficolin protein and methods of use thereof. The peptide may be a subsequence of human ficolin in which case it is essentially non-toxic. Further provided is a pharmaceutical composition including such peptides. The pharmaceutical composition can include an active ingredient for delivery through a body surface such as skin. | 03-08-2012 |
20120142613 | Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway - The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressed cells. | 06-07-2012 |
20120149651 | Caveolin peptides and their use as therapeutics - The present invention relates generally to compositions and methods useful for treating various conditions and afflictions, such as inflammation and cancer. More specifically, the present invention relates to compositions and methods of treatment which utilize peptides comprising at least one caveolin scaffolding domain. Even more specifically, the present invention relates to compositions of fusion peptides comprising the antennapedia homeodomain fused to a caveolin scaffolding domain and to methods of using these peptides to treat various conditions and afflictions. | 06-14-2012 |
20120220542 | PEGYLATED C-PEPTIDE - The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit superior pharmacokinetic and biological activity in vivo. | 08-30-2012 |
20120238509 | UROCORTIN 2 ANALOGS AND USES THEREOF - Disclosed are polypeptides that are analogs of urocortin 2 that have pharmacological activity similar to urocortin 2 but have improved water solubility compared to urocortin 2, and pharmaceutical compositions of the polypeptides of the present invention. Also disclosed are polynucleotides encoding the polypeptides, and methods of treating pathophysiological states employing pharmaceutical compositions of the polypeptides and polynucleotides of the present invention. In addition, disclosed are vectors and host cells that include a nucleic acid encoding a polypeptide of the present invention, and kits that include pharmaceutical compositions of the present invention. | 09-20-2012 |
20120258921 | PEPTIDES FOR THE TREATMENT OF HEARING - Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-α secretion through interaction with toll-like receptor signaling pathways. Experiments are described illustrating the efficacy of the compounds in treating otitis media, noise-induced hearing loss, age-related hearing loss, and improvement of ordinary hearing. | 10-11-2012 |
20120289472 | MOLECULES CAPABLE OF INDUCING CELL DEATH BY TARGETING THE MITOCHONDRIA AND APPLICATIONS THEREOF - The invention relates to the use of derivatives of the membrane insertion regions of proteins of the Bcl-2 family to induce cell death by targeting the mitochondria, characterised in that said derivatives are peptides belonging to regions α5 and/or α6 of the Bax protein or equivalent regions found in the other proteins of the Bcl-2 family. | 11-15-2012 |
20120309694 | Dual Chain Synthetic Heparin-Binding Growth Factor Analogs - The invention provides synthetic heparin-binding growth factor analogs having two peptide chains each branched from a branch moiety, such as trifunctional amino acid residues, the branch moieties separated by a first linker of from 3 to about 20 backbone atoms, which peptide chains bind a heparin-binding growth factor receptor and are covalently bound to a non-signaling peptide that includes a heparin-binding domain, preferably by a second linker, which may be a hydrophobic second linker. The synthetic heparin-binding growth factor analogs are useful as pharmaceutical agents, soluble biologics or as surface coatings for medical devices. | 12-06-2012 |
20130023485 | PARENTERAL FORMULATIONS OF PEPTIDES FOR THE TREATMENT OF SYSTEMATIC LUPUS ERYTHEMATOSUS - The subject invention provides a pharmaceutical composition comprising: an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of a pharmaceutically acceptable salt of a) a peptide comprising at least 12 and at most 30 consecutive amino acids, b) a peptide comprising consecutive amino acids having the sequence shown by any of SEQ ID NOS. 8-17, c) a peptide comprising consecutive amino acids having a sequence of any of a) and b), or at least two sequences in (a), or d) a peptide comprising consecutive amino acids having a sequence comprising at least two identical sequences included in (a); and a solubility enhancer; and wherein the composition has a pH between 4 and 9, and a method of alleviating symptoms of SLE in a human by administering an effective amount of the composition. | 01-24-2013 |
20130040899 | Use of PEDF-Derived Polypeptides for Treating Liver Cirrhosis - The present disclosure elucidates that 34-mer PEDF suppresses hepatic stellate cells (HSCs) from activation by diminishing the levels of alpha-smooth muscle actin (α-SMC), collagen type 1, and monocyte chemoattractant protein-1 (MCP-1); and 44-mer PEDF promotes liver regeneration process by enhancing the replication of liver-derived progenitor cells (LDPCs). Accordingly, methods and compositions directing to the new use of the 34-mer PEDF or 44-mer PEDF in patients suffering from liver cirrhosis are provided herein. | 02-14-2013 |
20130053330 | Fertilization Prediction and Promotion - The outcome of an in vitro fertilization (IVF) of a woman in terms of chances of successful pregnancy or the fertility status of a woman is predicted based on nucleotide analysis of the histidine-rich glycoprotein (HRG) gene or protein analysis of HRG. The proline isoform of HRG or an amino acid fragment thereof can further be used to increases the success of pregnancy of a woman. | 02-28-2013 |
20130059798 | Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway - The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells. | 03-07-2013 |
20130072446 | ANTI-INFLAMMATORY PHARMACEUTICAL PRODUCTS - Polypeptides having homology to regions of the N-terminal 50 residues of human Annexin 1 are provided for medical use as anti-inflammatory agents. Some of the polypeptides have homology to the N-terminal 48 residues of human Annexin 1, especially to residues 2-48 and 11-48 thereof. In some embodiments, properties of these compounds are improved by at least one modification at residues corresponding to residues 11, 22, 25 and/or 36 of human Annexin 1, and/or by C-terminal amidation of the polypeptide. Analogs of amino acids 2-26 of human Annexin 1, especially acetylated at the N-terminus and/or amidated at the C-terminus and having modifications at 11 and/or 22 are also disclosed for medical use as anti-inflammatory agents. | 03-21-2013 |
20130096072 | Zymogen Activators - Provided herein are zymogen activating molecules such as zymogen activating peptides, and methods of identifying and using these zymogen activating molecules such as zymogen activating peptides. | 04-18-2013 |
20130123201 | MODULATION OF CYTOKINE-INDUCED CHRONIC INFLAMMATORY RESPONSES - A composition for treatment of a chronic inflammation condition or an autoimmune disorder wherein the composition comprises a therapeutically effective amount of a polypeptide molecule comprising an amino acid sequence that shares at least 80% sequence identity with an amino acid sequence selected from SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO 23, and SEQ ID NO: 23. A composition for treatment of a chronic inflammation condition or an autoimmune disorder wherein the composition comprises a therapeutically effective amount of an analog of a LL-37 peptide molecule. A composition for treatment of a chronic inflammation condition or an autoimmune disorder wherein the composition comprises a therapeutically effective amount of an exogenous agonist for increasing cellular production and/or cellular activation and/or cellular expression of a LL-37 peptide. Use of one or more of the compositions for treatment of a chronic inflammation condition or an autoimmune disorder. | 05-16-2013 |
20130130993 | PIMAP39 MODULATES INFLAMMATORY RESPONSE - The present invention relates to a novel peptide sequence named PIMAP39 (herein referred to as SEQ ID NO.: 1) and methods of use of the novel sequence and functional variants thereof. The present invention also relates to methods for reducing and/or modulating inflammatory responses by administration of the peptide of the present invention. Furthermore, the present invention relates to the modulation of the expression of cytokines effected as part of an inflammatory response by administration of the peptide of the present invention. | 05-23-2013 |
20130130994 | ANTIMICROBIAL PEPTIDES AND PEPTIDE DERIVATIVES DERIVED FROM ONCOPELTUS FASCIATUS - The present invention relates to a antimicrobial peptide or peptide derivative comprising the following sequence: Sub | 05-23-2013 |
20130137645 | MODIFIED PEPTIDES AND PROTEINS - Provided are compounds and methods of making compounds containing two or three groups derived from a peptide, such as enfuvirtide or exenatide, covalently bound to a linker. The compounds may contain polyethylene glycol groups to enhance solubility and pharmacokinetic properties. The compounds are useful for the treatment of diseases or conditions subject to treatment with the parent peptide, such as HIV and AIDS in the case of enfuvirtide, or diabetes in the case of exenatide. | 05-30-2013 |
20130172275 | INHIBITING BINDING OF FGF23 TO THE BINARY FGFR-KLOTHO COMPLEX FOR THE TREATMENT OF HYPOPHOSPHATEMIA - The present invention is directed to a method of treating hypophosphatemia in a subject. This method involves selecting a subject with hypophosphatemia associated with elevated or normal FGF23 and administering to the selected subject an inhibitor of FGF23-Klotho-FGF receptor complex formation under conditions effective to treat the hypophosphatemia. The present invention is also directed to a method of screening for compounds suitable for treatment of hypophosphatemia associated with elevated or normal FGF23. This method involves providing FGF23, FGFR-Klotho complex, and one or more candidate compounds. The FGF23, the FGFR-Klotho complex, and the candidate compounds are combined under conditions effective for the FGF23 and the binary FGFR-Klotho complex to form a ternary complex if present by themselves. This method also involves identifying the candidate compounds, which prevent formation of the complex as being potentially suitable in treating hypophosphatemic conditions associated with elevated or normal FGF23. A method of screening the specificity of compounds which prevent formation of the FGF23-Klotho-FGFR complex is also disclosed. | 07-04-2013 |
20130190254 | POLYPEPTIDES THAT BIND MEMBRANE PROTEINS - Polypeptides which bind to the helical transmembrane region of membrane proteins are disclosed, as are methods for the design of polypeptides that bind to the transmembrane region of membrane proteins. Also provided are methods for the use of the disclosed polypeptides in various applications, as well as products made through the practice of the instant methods. | 07-25-2013 |
20130196933 | Methods and Compositions Inhibiting Tumor Cell Proliferation - The invention provides agents, compositions, pharmaceutical compositions and method for inhibiting tumor cell proliferation by inhibiting FoxM1B activity, expression, or nuclear localization in a tumor cell. | 08-01-2013 |
20130203683 | IMMUNOREGULATORY PEPTIDES AND METHODS OF USE - Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-α secretion through interaction with toll-like receptors. Experiments are described illustrating the efficacy of the compounds in treating otitis media | 08-08-2013 |
20130203684 | METHOD OF ACHIEVING A THYMOSIN BETA 4 CONCENTRATION IN A HUMAN PATIENT - The present invention provides embodiments which involve methods of providing a predetermined concentration of thymosin beta 4 (TB4) at a predetermined time, t, in a body portion of a live human patient. The methods can include determining a thymosin beta 4 treatment dosage (D) using Formula I: C=(A)D.t | 08-08-2013 |
20130210748 | METHOD AND PEPTIDE FOR REGULATING CELLULAR ACTIVITY - Method and peptide for regulating cellular activity includes a panel of synthesized peptides that have biological effects on inhibiting or enhancing cellular activity. Selected peptides can be used as therapy to reduce and/or inhibit, or initiate and/or enhance, an inflammatory response in a subject. | 08-15-2013 |
20130274206 | Compositions and Methods for Promoting Wound Healing and Tissue Regeneration - Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject. | 10-17-2013 |
20130281383 | NOVEL USES OF ELAFIN - The invention relates to novel uses of the polypeptide elafin, and/or homologies, derivatives or fragments thereof having inhibitory activity against leukocyte elastase for the prevention and treatment of medical conditions like SIRS. | 10-24-2013 |
20130296260 | METHOD FOR PREVENTION OR TREATMENT OF INTRACTABLE INFLAMMATORY BOWEL DISEASE - An object of the present invention is to provide methods for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease. The object can be achieved by a method for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease in a patient in need of the prevention or treatment of the inflammatory bowel disease, comprises administering an effective amount of adrenomedullin, a modified product thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, or a salt thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, to the patient. | 11-07-2013 |
20130345154 | Gap Junction-Enhancing Agents for Treatment of Necrotizing Enterocolitis and Inflammatory Bowel Disease - The present invention relates to methods of reducing the risk of occurrence of, and/or treating, necrotizing enterocolitis (“NEC”) or inflammatory bowel disease (“IBD”) comprising administering, to a subject in need of such treatment, an effective amount of a gap junction enhancing agent (“GJEA”), for example a peptide (“GJP”) or peptide analog (“GJPA”). It is based, at least in part, on the discovery that greater functionality of gap junctions between enterocytes increases their rate of migration and reduces the severity of intestinal inflammation. | 12-26-2013 |
20140005126 | SCAFFOLD PEPTIDES | 01-02-2014 |
20140005127 | METHODS OF TREATING MUSCULAR WASTING DISEASES USING NF-KB ACTIVATION INHIBITORS | 01-02-2014 |
20140088024 | Vesiculins - The inventions relate generally to vesiculin peptides and vesiculin peptide chains, and fragments, variants and derivatives thereof, related compositions and formulations and their preparation and use, nucleic acids encoding such vesiculin peptides and vesiculin peptide chains, and fragments, variants and derivatives thereof and related vectors and host cells, hybridomas and antibodies, and methods for the prevention and treatment of conditions, diseases and disorders that would be improved, eased, or lessened by the administration of a composition of the invention, including but not limited to glucose metabolism diseases. | 03-27-2014 |
20140107043 | NEW CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANIONIC POLYPEPTIDE FOR THE TREATMENT OF AIDS - This invention relates to a conjugated molecule comprising a peptide derived from the CD4 receptor coupled to an organic molecule by means of a linker as well as a process for its preparation. Said organic molecule comprises a 5 to 21 amino acid anionic polypeptide. Such a conjugated molecule can be used in antiviral treatment, namely in the treatment of AIDS. | 04-17-2014 |
20140142049 | PEGYLATED APELIN AND USES THEREOF - The invention provides compositions and methods for treating a disease or disorder associated with Apelin. Specifically, the invention relates to a pegylated form of Apelin to provide extended circulating life and inotropic effects, and thereby efficiently treat diseases or disorders associated with Apelin. | 05-22-2014 |
20140148397 | APPETITE STIMULATING PROTEIN - An engineered polypeptide comprising an AgRP analog with increased basic residues compared to the wild type polypeptide, wherein the polypeptide, when introduced into the CNS of a mammal, stimulates appetite. | 05-29-2014 |
20140206628 | Polypeptides for treating and/or limiting influenza infection - Polypeptides are disclosed herein, which recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection. | 07-24-2014 |
20140221296 | METHODS OF PHOSVITIN EXTRACTION AND PHOSPHOPEPTIDE PREPARATION FROM EGG YOLK - The invention is directed to methods for extracting phosvitin from egg yolk involving contacting the egg yolk or egg yolk protein granules with a solution having a salt concentration of about 10% to form a mixture; optionally, heating the mixture; adjusting the pH of the mixture to separate phosvitin from other proteins; recovering the phosvitin. The phosvitin extract may be dephosphorylated and hydrolyzed to produce phosvitin phosphopeptides. | 08-07-2014 |
20140235557 | Small Efficient Cell Penetrating Peptides Derived From The Scorpion Toxin Maurocalcine - The invention relates to small cell penetrating peptides (CPP) derived from the scorpion toxin maurocalcine and to their use as vectors for the intracellular delivery of various drugs and agents. | 08-21-2014 |
20140288010 | Compositions and Methods for Increasing Stem Cell Survival - Compositions and methods of increasing autophagy in a cell, or population of cells are disclosed. The methods generally include contacting the cell or cells with an effective amount of an agent that increases the bioavailability of an active isoform of SDF-1. Exemplary agents include active SDF-1 polypeptides, metformin, and DPP4 inhibitors. The methods can include administering the agent to a subject, or treating cells in vivo, in vitro or ex vivo. In some embodiments, cells are treated ex vivo and then transplanted into a subject. In a preferred embodiment, the cells are mesenchymal stem cells such as those found in bone marrow. The compositions and methods can be utilized in a number of therapeutic applications including increasing the longevity or survival of a graft or transplant, increasing the rate of recovery from an injury, reducing one or more symptoms of a chronic inflammatory disease and reducing effect associated with aging. | 09-25-2014 |
20140323414 | INOTROPIC COMPOUNDS - The present invention provides the use of a compound which activates at least one of the sodium channels: NAV 1.1, NAV 1.3, NAV 1.6 or a combination of two or more of such sodium channels, in the preparation of a medicament for increasing cardiac output. Moreover, the aim of the invention, is utilizing this compound for increasing cardiac output without affecting cardiac rhythm or without inducing cardiac rhythm disturbance. | 10-30-2014 |
20140357577 | HIV Membrane Fusion Inhibitors - The present invention concerns an inhibitor of Human Immunodeficiency Virus (HIV) fusion with, or HIV entry in, a host cell comprising at least 24, but preferably 26, contiguous amino acids; the invention also relates to a pharmaceutical composition comprising said amino acids. | 12-04-2014 |
20150018289 | NOVEL COMPOUNDS AND THEIR EFFECTS ON FEEDING BEHAVIOUR - The invention provides a peptide comprising the amino acid sequence given below, together with uses of the peptide and methods associated therewith. The peptide finds particular use as an appetite suppressant and in the treatment of obesity. | 01-15-2015 |
20150031633 | BIFUNCTIONAL PEPTIDE - The bifunctional peptide is capable of activating collagen synthesis and inhibiting the production of matrix metallo-proteinases. The peptide has a sequence including three peptide parts A, B and C. The first peptide part A corresponds to a hexapeptide repeated at least three times, the part A being capable of bonding to a receptor elastin-binding protein in order to stimulate collagen synthesis. The second peptide part B corresponds to a tetrapeptide capable of acting as a competitive inhibitor of urokinase protease and of being cleaved by said protease. The third peptide part C corresponds to a tripeptide occupying at least one active site of the matrix metallo-proteinases in order to enable inhibition of the proteinases. The present invention further concerns a cosmetic and/or pharmaceutical composition incorporating the bifunctional peptide. | 01-29-2015 |
20150072940 | Treatment of Obesity and Obesity-Related Disorders by Pharmalogical Targeting of Kv 1.3 Potassium Channels - Activation of brown adipose tissue, treatment of obesity and/or treatment of obesity-related disorders in human or non-human animal subjects by administering to the subject a potassium channel inhibiting agent. The potassium channel inhibiting agent may comprise ShK toxin or a modified ShK toxin. Examples of modified ShK toxins include ShK-186. | 03-12-2015 |
20150087603 | MODIFIED PEPTIDE TOXINS - The invention relates to toxin peptides capable of selectively inhibiting a Kv1.3 potassium channel protein. The toxin peptides of the invention are modified anuroctonus scorpion toxin peptides. | 03-26-2015 |
20150105334 | PEPTIDES DERIVED FROM NKP44 - The invention provides specific peptides derived from the cytotoxicity receptor NKp44 useful for preventing and treating serious diseases including in particular cancer. The invention further relates to compositions comprising a fragment of the extracellular region of NKp44 for preventing or treating cancer. | 04-16-2015 |
20150105335 | NOVEL PEPTIDE COMPOSITIONS - The present invention provides, among other things, novel peptides and compositions for treating disease. | 04-16-2015 |
20150119340 | FUSION PEPTIDE AND USE THEREOF FOR CELL MEMBRANE PENETRATING - A fusion peptide including a hydrophobic peptide and a basic peptide, a pharmaceutical composition including the fusion peptide, a cell membrane penetrating conjugate including the fusion peptide and a substance of interest, and a method for intracellular delivery of a substance of interest using the fusion peptide. | 04-30-2015 |
20150299277 | AGENT FOR TREATING OR PREVENTING SYSTEMIC INFLAMMATORY RESPONSE SYNDROME - The present invention provides a therapeutic or prophylactic agent for systemic inflammatory response syndrome (SIRS), which contains a polypeptide comprising an amino acid sequence the same or substantially the same as the amino acid sequence of the N-terminal domain of pentraxin 3 capable of binding to histone to form a polypeptide aggregate, or a pharmacologically acceptable salt thereof. The present invention also provides a reagent for quantification and a quantification method of histone, which utilize the polypeptide or a pharmacologically acceptable salt thereof. Furthermore, the present invention provides a polypeptide aggregate containing the polypeptide or a pharmacologically acceptable salt thereof and histone and a production method thereof. | 10-22-2015 |
20150299279 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISORDERS AND ALZHEIMER'S DISEASE AND IMPROVING NORMAL MEMORY - The disclosure relates generally to neurodegenerative disorders and more specifically to a group of presenilin/G-protein/c-src binding polypeptides and methods of use for modulating signaling and progression of Alzheimer's disease. | 10-22-2015 |
20150306178 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING TINNITUS - The invention relates to pharmaceutical compositions and methods for treating inner ear disorders. In particular, the invention provides a method for treating and/or preventing acute inner ear tinnitus in a subject in need thereof by administering a pharmaceutical composition comprising a peptide inhibitor of c-Jun N-terminal kinase. | 10-29-2015 |
20150307589 | PEPTIDIC ANTAGONISTS OF CLASS III SEMAPHORINS/NEUROPILINS COMPLEXES - The present invention concern a peptidic antagonist of class III semaphorins/neuropilins complexes comprising an amino acid sequence, which is derived from the transmembrane domain of a protein selected in the group consisting of neuropilin-1, neuropilin-2, plexin-A1, plexin-A2, plexin-A3, plexin-A4, Nr-CAM, L1-CAM, integrin Beta 1 and integrin beta 2, and including at least a GxxxG motif, eventually fused to an heterologous sequence; a nucleic acid encoding for said peptidic antagonist, a pharmaceutical composition comprising such a peptidic antagonist or a nucleic acid encoding thereof and uses thereof. | 10-29-2015 |
20150314011 | AMPHIPATHIC PEPTIDE - The present invention is directed to an amphipathic peptide and methods of using the amphipathic peptide for delivering small molecule agents to a cell. Ideally, the amphipathic cell penetrating peptide comprises less than approximately 50 amino acid residues with at least 6 arginine residues, at least 12 Alanine Residues, at least 6 leucine resiues, optionally at least one cysteine residue, and at least two but no greater than three glutamic acids wherein the arginine residues are evenly distributed along the length of the peptide; and the peptide has a defined ratio of arginine to negatively charged amino acid residues and a defined ratio of hydrophilic amino acid residues to hydrophobic amino acid residues. The present invention is also directed to a nanoparticle and cell delivery system comprising the amph ipathic cell penetrating peptide of the invention. The peptide, nanoparticle or cell delivery sys tem of the invention may be used in therapy. For example, the peptide may be used as a therapeutic agent delivery system, in which the therapeutic agent may include nucleic acids or other small molecules. | 11-05-2015 |
20150315245 | Peptide Compounds and Methods of Production and Use Thereof - Peptide compounds based on the CAP37 (cationic antimicrobial protein of M | 11-05-2015 |
20150315256 | Anti-Inflammatory Pharmaceutical Products - Polypeptides having homology to regions of the N-terminal 50 residues of human Annexin 1 are provided for medical use as anti-inflammatory agents. Some of the polypeptides have homology to the N-terminal 48 residues of human Annexin 1, especially to residues 2-48 and 11-48 thereof. In some embodiments, properties of these compounds are improved by at least one modification at residues corresponding to residues 11, 22, 25 and/or 36 of human Annexin 1, and/or by C-terminal amidation of the polypeptide. Analogs of amino acids 2-26 of human Annexin 1, especially acetylated at the N-terminus and/or amidated at the C-terminus and having modifications at 11 and/or 22 are also disclosed for medical use as anti-inflammatory agents. | 11-05-2015 |
20150343095 | Cell Penetrating Peptide, Conjugate Comprising Same, and Composition Comprising Conjugate - The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 178, a fragment of any one sequence of SEQ ID NO: 2 to SEQ ID NO: 178, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed. | 12-03-2015 |
20150361135 | POLYPEPTIDE SPECIFICALLY BINDING TO RARE EARTH NANOPARTICLES AND USE THEREOF - The present invention provides a polypeptide able to specifically bind to rare-earth nanoparticles and the use thereof. The polypeptide comprises an amino acid sequence shown by SEQ ID NO: 1 or analogues thereof. The present invention further provides a method for screening a polypeptide having the capacity of specifically binding to rare-earth nanoparticles. The present invention further provides a method for regulating and controlling the in vivo and in vitro autophagy and toxicity of the rare-earth upconversionnanophosphor material, comprising mixing and incubating the polypeptide specifically binding to rare-earth nanoparticles with rare-earth upconversion nanophosphor material, such that the polypeptide specifically binds to the nanophosphor material, wherein the rare-earth upconversion nanophosphor material comprises the rare earth, and the polypeptide specifically binding to rare-earth nanoparticles comprises the amino acid sequence shown by CTARSPWIC (RE-0, SEQ ID NO: 1) or analogues thereof. | 12-17-2015 |
20150374779 | PHARMACOLOGIC TREATMENTS OF MENIERE'S DISEASE - The invention relates to pharmaceutical compositions and methods for treating Meniére's Disease. In particular, the invention provides a method for treating Meniére's Disease in a subject in need thereof by administering a pharmaceutical composition comprising a peptide inhibitor of c-Jun N-terminal kinase. | 12-31-2015 |
20150374844 | NOVEL PH -SWITCHABLE PEPTIDES FOR MEMBRANE INSERTION AND PORE FORMATION - Disclosed herein is a pH-switchable pore formation (PSPF) peptide comprising one or more amino acids in peptide sequence whose charge state and hydrophobicity are pH-dependent, wherein the peptide can bind to a biological membrane upon contact and form pores on the membrane at pH of less than about 7, and wherein the peptide forms substantially no pores on the biological membrane at pH of greater than about 7. Also disclosed is a modular composition comprising: a) one or more PSPF peptides, which may be the same or different; b) a single stranded or double stranded oligonucleotide; and c) one or more linkers, which may be the same or different. | 12-31-2015 |
20150376238 | Polypeptides for Treating and/or Limiting Influenza Infection - Disclosed herein are polypeptides that bind to the hemagglutinin protein of influenza virus, and which can be used for treating and diagnosing influenza infection. | 12-31-2015 |
20160009772 | CELL PENETRATING PEPTIDES WHICH BIND IRF5 | 01-14-2016 |
20160022780 | UROCORTIN 2 ANALOGS AND USES THEREOF - Disclosed are polypeptides that are analogs of urocortin 2 that have pharmacological activity similar to urocortin 2 but have improved water solubility compared to urocortin 2, and pharmaceutical compositions of the polypeptides of the present invention. Also disclosed are polynucleotides encoding the polypeptides, and methods of treating pathophysiological states employing pharmaceutical compositions of the polypeptides and polynucleotides of the present invention. In addition, disclosed are vectors and host cells that include a nucleic acid encoding a polypeptide of the present invention, and kits that include pharmaceutical compositions of the present invention. | 01-28-2016 |
20160022828 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES - The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer. | 01-28-2016 |
20160031945 | MATERIALS AND METHOD FOR SUPPRESSING INFLAMMATORY AND NEUROPATHIC PAIN - N-type voltage-gated calcium channels (CaV2.2) are critical mediators of neurotransmitter release and are thought to be involved with transmission of nociception. The use of conventional CaV2.2 blockers in pain therapeutics is limited by side effects. Reported herein is a means to suppress both inflammatory and neuropathic pain without directly blocking CaV2.2, but rather by inhibiting the binding of the axonal collapsin response mediator protein 2 (CRMP-2), a protein known to enhance CaV2.2 function. A 15 amino acid peptide of CRMP-2 fused to the protein transduction domain of the HIV tat protein (TAT CBD3) reduced meningeal blood flow induced by activation of the trigeminovascular system, prevented inflammation-induced tactile hypernociception induced by intraplantar formalin and nocifensive behavior following corneal capsaicin application, and reversed neuropathic hypernociception produced by the antiretroviral drug 2′,3′-dideoxycytidine. Preventing CRMP-2-mediated enhancement of CaV2.2 function suppressed inflammatory and neuropathic nociception, providing a method for treating pain and inflammation. | 02-04-2016 |
20160031967 | POLYPEPTIDES - The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX | 02-04-2016 |
20160032278 | SCAFFOLD PROTEINS DERIVED FROM PLANT CYSTATINS - The present invention relates to scaffold proteins derived from plant cystatins and to nucleic acids encoding them. The scaffolds are highly stable and have the ability to display peptides. The scaffolds are particularly well suited for constructing libraries, e.g., in phage display or related systems. The invention also relates to various uses of the scaffolds, including in therapy, diagnosis, environmental and security monitoring, synthetic biology and research, and to cells and cell cultures expressing the scaffold proteins. | 02-04-2016 |
20160039901 | INHIBITORS OF TLR SIGNALING BY TARGETING TIR DOMAIN INTERFACES - TIR-domain decoy peptides and TIR domain peptides are disclosed, as well as methods of using the peptides in the regulation of toll-like receptor (TLR) activation and signaling. | 02-11-2016 |
20160051485 | Biodegradable Bionanoparticles for Releasing the GSE24-2 Peptide, Method for the Production Thereof, and Use of Same - The invention relates to biodegradable PLGA bionanoparticles encapsulating the GSE24-2 peptide with telomerase activity and to pharmaceutical, cosmetic and biotechnological compositions comprising same. The pharmaceutical compositions are useful for treating diseases presenting a telomerase deficiency, such as dyskeratosis congenita, and diseases presenting ageing characteristics, such as Werner syndrome, Rothmund Thompson syndrome, and other diseases where there is DNA damage such as ataxia telangiectasia. The invention likewise relates to the method for producing said bionanoparticles by means of a w/o/w double emulsion technique. | 02-25-2016 |
20160075746 | TAILORING MULTIVALENT INTERACTIONS OF BIOPOLYMERS WITH A POLYPROLINE SCAFFOLD - A glycopeptide, comprising a polyproline backbone and one or more carbohydrate molecules. | 03-17-2016 |
20160120950 | Pharmaceutical Formulations Comprising Incretin Mimetic Peptide and Aprotic Polar Solvent - The present disclosure is directed to stable pharmaceutical formulations and uses thereof. | 05-05-2016 |
20160129081 | Oral Treatment Of Inflammatory Bowel Disease - Treatment of an inflammatory bowel disease in a subject in need thereof by simultaneous or successive parenteral and oral administration of a mammalian beta defensin is described. Oral administration of mammalian beta defensin to a subject during remission to keep said subject suffering from IBD in remission, prolong remission in said subject suffering from IBD, to reduce the occurrence of relapse in said subject suffering from IBD, or any combination thereof, is also described. | 05-12-2016 |
20160152672 | Reagents and Methods for Treating Dental Disease | 06-02-2016 |
20160185833 | PEPTIDES - The present invention provides a peptide at least partially derivable from human Thyroid Stimulating Hormone Receptor (TSHR) which peptide is capable of binding to an MHC molecule in vitro and being presented to a T cell without further antigen processing. The present invention also relates to the use of such peptides for the prevention or suppression of activating autoantibody formation in Graves' Disease. | 06-30-2016 |
20160199446 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | 07-14-2016 |
20180022780 | STABILIZATION ADRENOMEDULLIN DERIVATIVES AND USE THEREOF | 01-25-2018 |
20180022786 | NOVEL SODIUM CHANNEL BLOCKING PEPTIDES AND THE USE THEREOF | 01-25-2018 |